World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
94
Citations
55523
World Ranking
10252
National Ranking
5272

Overview

Joan H. Schiller is affiliated with the University of Virginia in the United States. Their research work primarily spans the field of Medicine, with a significant focus on Pulmonary and Respiratory Medicine, Oncology, Health, Toxicology and Mutagenesis, Economics and Econometrics, and Public Health, Environmental and Occupational Health.

The scientist's research emphasizes topics related to Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Climate Change and Health Impacts, Air Quality and Health Impacts, Lung Cancer Research Studies, Cystic Fibrosis Research Advances, and Cancer Immunotherapy and Biomarkers.

Frequent coauthors in Joan H. Schiller's research include Stephanie Thee, Mirjam Stahl, J. Tattersall-Wong, Fredine T. Lauer, and Arryn Ketter.

Joan H. Schiller has published extensively in several journals. The most common publication venues are:

  • Journal of Cystic Fibrosis
  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • UNC Libraries
  • The Oncologist

Recent publications by Joan H. Schiller include:

  • Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update, 2020, Journal of Clinical Oncology
  • Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update, 2021, Journal of Clinical Oncology
  • Air Pollution and Lung Cancer: A Review by International Association for the Study of Lung Cancer Early Detection and Screening Committee, 2023, Journal of Thoracic Oncology
  • Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2022, Journal of Clinical Oncology
  • Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2022, Journal of Clinical Oncology

Best Publications

  • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

    Alan Sandler;Robert Gray;Michael C. Perry;Julie Brahmer

  • Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

    Joan H. Schiller;David Harrington;Chandra P. Belani;Corey Langer

  • Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial

    Mark G. Kris;Ronald B. Natale;Roy S. Herbst;Thomas J. Lynch

  • Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

    Roy S. Herbst;Giuseppe Giaccone;Joan H. Schiller;Ronald B. Natale

  • Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

    Giuseppe Giaccone;Roy S. Herbst;Christian Manegold;Giorgio Scagliotti

  • Lung cancer in never smokers — a different disease

    Sophie Sun;Joan H. Schiller;Adi F. Gazdar

  • Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

    Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski

  • Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

    Joachim von Pawel;Joan H. Schiller;Frances A. Shepherd;Scott Z. Fields

  • [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].

    Christopher G. Azzoli;Sherman Baker;Sarah Temin;William Pao

  • Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis

    Andrea Ardizzoni;Luca Boni;Marcello Tiseo;Frank V. Fossella

  • Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

    Gregory A. Masters;Sarah Temin;Christopher G. Azzoli;Giuseppe Giaccone

  • Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer

    Panos M. Fidias;Shaker R. Dakhil;Alan P. Lyss;David M. Loesch

  • Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599

    A. B. Sandler;R. Gray;J. Brahmer;A. Dowlati

  • Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599

    Suresh S. Ramalingam;Suzanne E. Dahlberg;Corey J. Langer;Robert Gray

  • Mass Spectrometry to Classify Non–Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study

    Fumiko Taguchi;Benjamin Solomon;Vanesa Gregorc;Heinrich Roder

  • Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer

    Lecia V. Sequist;Joachim von Pawel;Edward G. Garmey;Wallace L. Akerley

  • Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.

    T Le Chevalier;G Scagliotti;R Natale;S Danson

  • Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

    Nasser H. Hanna;Bryan J. Schneider;Sarah Temin;Sherman Baker

  • Topotecan Versus Observation After Cisplatin Plus Etoposide in Extensive-Stage Small-Cell Lung Cancer: E7593—A Phase III Trial of the Eastern Cooperative Oncology Group

    Joan H. Schiller;Sudeshna Adak;David Cella;Russell F. DeVore

  • Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer

    Mark G. Kris;Ronald B. Natale;Roy S. Herbst;Diane Prager

Frequent Co-Authors

David H. Johnson
David H. Johnson The University of Texas Southwestern Medical Center
Ernest C. Borden
Ernest C. Borden Cleveland Clinic
Suresh S. Ramalingam
Suresh S. Ramalingam Emory University
Paul M. Sondel
Paul M. Sondel University of Wisconsin–Madison
Jacquelyn A. Hank
Jacquelyn A. Hank University of Wisconsin–Madison
Chandra P. Belani
Chandra P. Belani Penn State Cancer Institute
Roy S. Herbst
Roy S. Herbst Yale University
Julie R. Brahmer
Julie R. Brahmer Johns Hopkins University
James K V Willson
James K V Willson The University of Texas at Dallas
Minesh P. Mehta
Minesh P. Mehta University of Maryland, Baltimore

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always start with medical school. There are multiple online degree options that offer flexible entry points into healthcare. For those interested in health information management, billing and coding classes online provide practical skills for one of the fastest-growing fields in the industry.

Nursing offers one of the most diverse and in-demand career pathways. Aspiring nurse leaders can advance their practice with nurse practitioner programs, many of which are available fully online. For those seeking affordable graduate options, the cheapest online MSN programs allow registered nurses to earn their master’s degree without putting their career on hold.

If you’re considering advanced roles in teaching, research, or healthcare leadership, online nursing doctoral programs can provide the highest level of training in the field. Whether you’re starting with entry-level credentials or aiming for a doctorate, these online pathways offer flexibility, accessibility, and a broad spectrum of healthcare career opportunities.

Best Scientists Citing Joan H. Schiller

Trending Scientists

Recently Published Articles